Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: January 24, 2024
Subject: Announcement of results of operations for the fourth quarter and full year 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced and directs readers to Exhibit 99.1 (the Press Release) for detailed figures.
The filing notes the use of non-GAAP financial measures, specifically "net earnings excluding specified items," which adjust for:
- Acquisition-related expenses and restructuring actions.
- Cost reduction initiatives and voluntary recall costs.
- Intangible asset impairment charges and fair value adjustments to contingent consideration.
- Certain regulatory costs and tax benefits associated with specified items.
- Intangible amortization expense.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It references the full year 2023 results but does not quantify the year-over-year performance within this document.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures provide useful information for evaluating ongoing business performance and are used internally to monitor business performance. However, the company cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Risks and Contingencies: The filing lists factors excluded from non-GAAP measures that represent potential risks or unusual items, including voluntary recalls, intangible asset impairments, and resolution of prior-year tax positions.
Guidance: The filing text does not contain specific forward-looking guidance or outlook figures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 24, 2024) for specific Q4 and full-year 2023 revenue and earnings figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings to understand the impact of excluded items (e.g., restructuring, impairments, tax adjustments).
- Assess the magnitude of intangible amortization expense excluded from non-GAAP results.
- Confirm details regarding the "voluntary recall" and "intangible asset impairments" mentioned as adjustments.